Acquired Company

Vertex Pharmaceuticals completed the acquisition of Alpine Immune Sciences for $65 per share in cash, for a total value of approximately $4.9 billion, with Alpine delisted from Nasdaq on May 19, 2024.

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune / inflammatory disorders, and other diseases. The company is headquartered in Seattle, Washington. Show more

188 EAST BLAINE STREET, SEATTLE, WA, UNITED STATES, 98102, Washington, 98102, USA

https://www.alpineimmunesciences.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

4.457B

52 Wk Range

$0.00 - $0.00

Previous Close

$64.97

Open

$64.97

Volume

N/A

Day Range

$64.97 - $64.97

Enterprise Value

0.00

Cash

33.02M

Avg Qtr Burn

-27.69M

Insider Ownership

4.65%

Institutional Own.

99.47%

Qtr Updated

03/31/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Acazicolcept (ALPN-101) Details Systemic lupus erythematosus	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Povetacicept (ALPN-303) Details Autoimmune disease, Autoimmune nephritis, Immune complex membranoproliferative glomerulonephritis, IgA nephropathy	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Povetacicept (ALPN-303) Details Autoimmune disease, Systemic lupus erythematosus	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Povetacicept (ALPN-303) Details Autoimmune disease, Primary immune thrombocytopenia	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Davoceticept (ALPN-202) (CD28 costimulator) Details Advanced malignancies	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.